Últimas noticias sobre Lantheus Holdings (NASDAQ:LNTH) Bolsa

Lantheus Holdings

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings Inc

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) has outperformed the market over the past 5 years by 23.29% on an annualized basis producing an average annual return of 36.08%. Currently, Lantheus Holdings has a market capitalization of $6.19 billion. 
Buying $1000 In LNTH: If an investor had bought $1000 of LNTH stock 5 years ago, it would be worth $4,630.01 today based on a price of $89.16 for LNTH at the time of writing.
<h3>Lantheus Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735920908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

LNTH

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

A substantial insider activity was disclosed on December 24, as MARKISON, CEO at Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), reported the exercise of a large sell of company stock options.
What Happened: MARKISON, CEO at Lantheus Holdings, made a strategic move by exercising stock options for 32,768 shares of LNTH as detailed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001521036/000106299324021182//Archives/edgar/data/1521036/000106299324021182/0001062993-24-021182-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $2,731,057.
Lantheus Holdings shares are trading, exhibiting up of 1.64% and priced at $92.5 during Tuesday's morning. This values MARKISON's 32,768 shares at $2,731,057.
<h3>About Lantheus Holdings</h3>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
<h3>Lantheus Holdings's Economic Impact: An Analysis</h3>
Positive Revenue Trend: Examining Lantheus Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.37% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 63.93%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Lantheus Holdings's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.89.
</li>
</ul>
Debt Management: Lantheus Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.52, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 15.12 is lower than the industry average, implying a discounted valuation for Lantheus Holdings's stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 4.32 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lantheus Holdings's EV/EBITDA ratio at 9.32 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001521036">Check Out The Full List Of Lantheus Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Options Exercise: BRIAN MARKISON At Lantheus Holdings Realizes $2.73M

In the current session, the stock is trading at $93.06, after a 0.44% spike. Over the past month, Lantheus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock increased by 7.65%, and in the past year, by 56.81%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_0.png" alt="Past Year Chart" />

<h3>Lantheus Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Lantheus Holdings has a lower P/E than the aggregate P/E of 48.6 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Lantheus Holdings

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Paul Choi initiated coverage on Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announced a price target of $143. Lantheus shares closed at $92.66 on Tuesday. See how other analysts view this stock.</li>
<li>DA Davidson analyst Lucky Schreiner initiated coverage on Box, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) with a Buy rating and announced a price target of $45. Box shares closed at $32.07 on Tuesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Brookline Capital analyst Kumaraguru Raja initiated coverage on Quince Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy rating and announced a price target of $9. Quince Therapeutics shares closed at $1.84 on Tuesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Tazeen Ahmad initiated coverage on KalVista Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Buy rating and announced a price target of $22. KalVista Pharma shares closed at $8.65 on Tuesday. See how other analysts view this stock.</li>
<li>Raymond James analyst Andrew Marok initiated coverage on DoubleVerify Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with an Outperform rating and announced a price target of $25. Fluor shares closed at $19.95 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BOX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="507" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-1024x507.png" alt="" class="wp-image-697929" style="width:604px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-1024x507.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42551008/top-3-health-care-stocks-that-may-explode-in-q4">Read This Next: </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42551008/top-3-health-care-stocks-that-may-explode-in-q4">Top 3 Health Care Stocks That May Explode In Q4</a></li>
</ul>

Initiation

Analyst Ratings

KALV

QNCX

This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Goldman Sachs analyst Paul Choi initiates coverage on Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announces Price Target of $143.

Price Target

Goldman Sachs Initiates Coverage On Lantheus Holdings with Buy Rating, Announces Price Target of $143

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) has outperformed the market over the past 5 years by 20.97% on an annualized basis producing an average annual return of 34.66%. Currently, Lantheus Holdings has a market capitalization of $6.35 billion. 
Buying $1000 In LNTH: If an investor had bought $1000 of LNTH stock 5 years ago, it would be worth $4,461.65 today based on a price of $91.42 for LNTH at the time of writing.
<h3>Lantheus Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734102018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Lantheus Holdings Stock In The Last 5 Years

Lantheus Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NYSE">LNTH</a>) short percent of float has risen 6.28% since its last report. The company recently reported that it has 4.45 million shares sold short, which is 8.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lantheus Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733841017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lantheus Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lantheus Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lantheus Holdings's peer group average for short interest as a percentage of float is 6.33%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Lantheus Holdings?

WIIM

Lantheus Holdings shares are trading higher after the company announced its board authorized a $250 million share repurchase program.

Buybacks

Lantheus Board Authorizes $250M Share Repurchase Program

Lantheus Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NYSE">LNTH</a>) short percent of float has risen 3.19% since its last report. The company recently reported that it has 4.25 million shares sold short, which is 8.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lantheus Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731351612_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lantheus Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lantheus Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lantheus Holdings's peer group average for short interest as a percentage of float is 7.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

<h3 class="wp-block-heading">Trump Will Fix It&nbsp;</h3>
In my previous post (<a href="https://www.zerohedge.com/news/2024-11-06/post-trump-victory-trade">The Post-Trump Victory Trade</a>), I highlighted a half dozen stocks in which my subscribers and I had positions that had double digit gains the day after Trump&#8217;s election victory. In response, a commenter wrote, &#8220;Well, I didn&#8217;t like any of those trades, so I will stick to my Gold and Silver.&#8221;.&nbsp;
As it happened, the day after Trump&#8217;s victory, was also the day of the &#8220;<a href="https://www.zerohedge.com/the-market-ear/great-gold-puke">Great Gold Puke</a>&#8220;, as The Market Ear put it:&nbsp;
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><h3 class="wp-block-heading">All good things&#8230;</h3>
&#8230;.must come to an end. Gold is puking, putting in the biggest down candle in forever as it breaks below the short term trend channel. The 50 day comes in around $2635, and the bigger trend line around $2600.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="532" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-1024x532.png" alt="" class="wp-image-3141" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-1024x532.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-300x156.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-768x399.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> 
<cite>Refinitiv</cite></blockquote>
Why would gold tumble after Trump&#8217;s victory? Perhaps there&#8217;s a clue in the Trump campaign&#8217;s slogan, &#8220;Trump will fix it&#8221;. One of the things Trump will fix is the elevated geopolitical risk the world has seen over the last few years, starting with the Russia-Ukraine War, and extending to the wars in the Mideast between Israel and Hamas, and Israel and Iran, and tensions between China and Taiwan.&nbsp;
<h3 class="wp-block-heading">Geopolitical Risk Is Already Starting To Ebb</h3>
The geopolitical risk premium is a key factor influencing the price of precious metals like gold and silver, as they are traditionally seen as a haven during times of instability and war. Given that, note what has happened since Trump&#8217;s victory:&nbsp;
<ul>
<li>Hamas <a href="https://x.com/DonaldJTrumpJr/status/1854516506169585796">has called for</a> an end to its war with Israel. </li>
<li>Russian President Vladimir Putin&nbsp;<a href="https://www.zerohedge.com/geopolitical/putin-praises-courageous-trump-hints-ukraine-talks-phone-call-likely">has congratulated Trump</a>&nbsp;on his victory, praised Trump&#8217;s bravery during the first assassination attempt on him, and expressed an openness toward talks aimed at ending the Ukraine war. Peace between the U.S. and Russia would facilitate peace in the Mideast and elsewhere, given Russia&#8217;s ties to Iran, China, and other key countries.&nbsp;</li>
<li>China&#8217;s President Xi <a href="https://x.com/XHNews/status/1854396381982830623">also extended congratulations</a> and an olive branch to Trump.</li>
</ul>
If Trump succeeds in ending the wars in Eastern Europe and the Mideast, and calming tensions across the Taiwan Strait, that would further reduce gold&#8217;s geopolitical risk premium.&nbsp;
<h3 class="wp-block-heading">The Deflationary Potential Of Trump&#8217;s Domestic Policies </h3>
You&#8217;re probably thinking now that even if peace starts to break out, high inflation is baked into the cake because of government spending, and that should boost the price of gold. Consider, though, the deflationary potential of Trump&#8217;s proposed policies, and those of his close allies.&nbsp;&nbsp;
<ul>
<li>Trump&#8217;s tariffs. Critics of tariffs often point out that they are, effectively, a regressive tax on domestic consumers. This is actually true, and like all regressive taxes, they are deflationary. Just as throwing money and low income Americans boosted inflation during COVID, an effective regressive tax on them would cool inflation.&nbsp;</li>
<li>Trump&#8217;s deportations.&nbsp;Deporting millions of illegal aliens&#8211;or deporting a smaller number and prompting millions more to self-deport&#8211;will have a deflationary effect on sectors such as housing, as there will be fewer consumers competing for the same number of homes.&nbsp;</li>
<li>RFK, Jr.&#8217;s campaign against chronic disease. Every case of diabetes and other chronic diseases RFK, Jr. can prevent with changes to American food policy means a reduction of tens of thousands, if not hundreds of thousands of dollars in health care spending. That would cool healthcare inflation.&nbsp;</li>
<li>Elon Musk&#8217;s Department Of Government Efficiency. Elon Musk has spoken about slashing the number of federal employees (something Vivek Ramaswamy pointed out could be done while avoiding Civil Service regulations) and cutting government waste. That would be deflationary too.&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Much Of This Is Likely To Happen&nbsp;</h3>
We all remember how Trump was stymied in his first term, but he is in a much stronger position now. He won a landslide victory, and is now the undisputed leader of the Republican Party. Plus, he has much smarter, and more competent people on his side now, such as Elon Musk. None of this is particularly good for gold and silver prices.&nbsp;
<h3 class="wp-block-heading">Taking My Own Counsel&nbsp;</h3>
On Thursday, I exited the two gold positions I had, in&nbsp;Olra Mining&nbsp;(ORLA) and IAMGOLD&nbsp;(IAG), as you can see below, in my list of trade exits for this week.&nbsp;
Stocks or Exchange Traded Products
<ol>
<li>Lantheus Holdings&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>). Bought at $94.84 on&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-8152024/comment/65674302" target="_blank" rel="noreferrer noopener">8/16/2024</a>; stopped out at $96.99 on&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-8152024/comment/75900731" target="_blank" rel="noreferrer noopener">11/6/2024</a>.&nbsp;Profit: 2.3%.</li>
<li>Orla Mining&nbsp;(<a href="https://substack.com/discover/stocks/ORLA" target="_blank" rel="noreferrer noopener">ORLA 4.11%↑</a>). Bought for an effective price of $2.90 on&nbsp;<a href="https://portfolioarmor.substack.com/p/an-oversold-gold-miner" target="_blank" rel="noreferrer noopener">11/17/2023</a>&nbsp;(I sold $5 strike puts on it for $2.10, and those puts exercised on 11/17/2023); sold for $4.60 on&nbsp;<a href="https://portfolioarmor.substack.com/p/an-oversold-gold-miner/comment/76086457" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 59%.</li>
</ol>
Options
<ol>
<li>Call spread on&nbsp;Super Micro Computer&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>). Entered at a net debit of $0.33 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-ai-da2" target="_blank" rel="noreferrer noopener">11/4/2024</a>; will expire worthless on 11/8/2024.&nbsp;Loss: 100%.</li>
<li>Calls on&nbsp;IAMGOLD&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>). Bought for $0.75 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-gold" target="_blank" rel="noreferrer noopener">10/8/2024</a>; sold (second half) for $1.15 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-gold/comment/76091886" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 53%.</li>
<li>Calls on&nbsp;Emergent BioSolutions&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>). Bought for $2.05 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-biotech" target="_blank" rel="noreferrer noopener">8/30/2024</a>; sold for $4.10 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-biotech/comment/76086955" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 100%.</li>
<li>Call spread on TG Therapeutics (<a href="https://substack.com/discover/stocks/TGTX" target="_blank" rel="noreferrer noopener">TGTX 2.33%↑</a>). Entered at net debit of $0.33 on <a href="https://portfolioarmor.substack.com/p/trade-alert-biotech" target="_blank" rel="noreferrer noopener">8/30/2024</a>; exited at a net credit of $0.94 on <a href="https://portfolioarmor.substack.com/p/trade-alert-biotech/comment/76253379" target="_blank" rel="noreferrer noopener">11/8/2024</a>. Profit: 184%.</li>
<li>Call spread on&nbsp;Tesla&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>). Entered at a net debit of $1.63 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-evs/comment/76235063" target="_blank" rel="noreferrer noopener">4/8/2024</a>; exited at net credit of $4.74 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-evs/comment/76235063" target="_blank" rel="noreferrer noopener">11/8/2024</a>.&nbsp;Profit: 191%.</li>
<li>Call spread on&nbsp;Innodata&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>). Entered at $0.33 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-24f" target="_blank" rel="noreferrer noopener">8/13/2024</a>; exited at $0.97 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-24f/comment/76235562" target="_blank" rel="noreferrer noopener">11/8/2024</a>.&nbsp;Profit: 194%.</li>
<li>Call spread on&nbsp;Powell Industries&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>). Entered at a net debit of $1.60 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-industrial" target="_blank" rel="noreferrer noopener">8/13/2024</a>; exited at a net credit of $4.75 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-industrial/comment/76088210" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 197%.</li>
<li>Calls on&nbsp;Travelzoo&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>). Bought at $1 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-crypto" target="_blank" rel="noreferrer noopener">7/23/2024</a>; sold (half) at $8.30 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-crypto/comment/75897738" target="_blank" rel="noreferrer noopener">11/6/2024</a>.&nbsp;Profit: 730%.</li>
</ol>
<h2 class="wp-block-heading">The Post-Trump Victory Trade We&#8217;re Buying Now</h2>
Trump&#8217;s victory means China is going to have to stimulate its economy more aggressively (because it won&#8217;t be able to export as much to the U.S. with Trump&#8217;s tariff).&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;Donald Trump's second US presidency is likely to prompt aggressive China stimulus&quot; &#8211; Devan Kaloo, global head of equities at abrdn <a href="https://t.co/hVPBus1Bde">https://t.co/hVPBus1Bde</a>
&mdash; zerohedge (@zerohedge) <a href="https://twitter.com/zerohedge/status/1854379142952726692?ref_src=twsrc%5Etfw">November 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
That stimulus will boost companies doing business in China&#8217;s domestic market. One of those companies hit our&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-1172024">top ten names</a>&nbsp;last night, and my subscribers and I placed a trade on it today.&nbsp;
<figure class="wp-block-image size-full is-resized"><a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-trump-china"><img loading="lazy" decoding="async" width="922" height="816" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade.jpg" alt="" class="wp-image-3142" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade.jpg 922w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade-300x266.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade-768x680.jpg 768w" sizes="(max-width: 922px) 100vw, 922px" /></a><figcaption class="wp-element-caption">Click on the image to go to the post. </figcaption></figure>
If you&#8217;d like a heads up when we place our next trade, feel free to subscribe to our trading Substack/occasional email list below.&nbsp;
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204717/Widget-1.jpg" alt="" class="wp-image-3152" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204717/Widget-1.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204717/Widget-1-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>
And if you are concerned about market risk, you can download our optimal hedging app by pointing your iPhone camera at the QR code below, or by clicking on it. 
<figure class="wp-block-image size-full"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204833/QR-Code-2.jpg" alt="" class="wp-image-3155" /></a></figure>

Commodities

Economics

General

INOD

POWL

SMCI

TSLA

TZOO

After Trump's Win, It's Time To Take Profits On Gold

Truist Securities analyst Richard Newitter reiterates Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and lowers the price target from $135 to $120.

Reiteration

Truist Securities Reiterates Buy on Lantheus Holdings, Lowers Price Target to $120

JMP Securities analyst David Turkaly maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Market Outperform and lowers the price target from $125 to $112.

JMP Securities Maintains Market Outperform on Lantheus Holdings, Lowers Price Target to $112

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 77.9% to $7.49 during Wednesday's regular session. The company's market cap stands at $38.9 million. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares moved upwards by 29.22% to $7.03. The company's market cap stands at $924.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) stock increased by 23.78% to $7.13. The market value of their outstanding shares is at $443.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 21.63% to $2.98. The company's market cap stands at $104.0 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock moved upwards by 21.26% to $0.34. The market value of their outstanding shares is at $10.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 16.24% to $5.94. The company's market cap stands at $108.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) stock declined by 39.6% to $3.13 during Wednesday's regular session. The company's market cap stands at $335.3 million. As per the press release, Q3 earnings came out today. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 39.39% to $17.91. The market value of their outstanding shares is at $2.7 billion. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock declined by 31.98% to $0.09. The market value of their outstanding shares is at $1.5 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 31.5% to $1.74. The market value of their outstanding shares is at $1.8 million. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 27.36% to $51.95. The company's market cap stands at $9.5 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock decreased by 22.71% to $88.86. The market value of their outstanding shares is at $6.1 billion. As per the news, the Q3 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BJDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CTKB

EXAS

OPRX

PACS

RAPT

SONN

TMCI

TNGX

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

Lantheus Holdings shares are trading lower. The company reported Q3 financial results and narrowed its FY24 guidance.

Full Year 2024 Financial Guidance&nbsp; Guidance Issued November 6, 2024 Guidance Issued July 31, 2024 FY 2024 Revenue $1.51 billion - $1.52 billion $1.50 billion - $1.52 billion FY 2024 Adjusted Fully Diluted EPS $6.65 - $6.70 $6.60 - $6.70

Earnings

Guidance

Lantheus Narrows 2024 Guidance: Now Sees Revenue Of $1.51B-$1.52B (Prior $1.50B-$1.52B) Vs. $1.52B Est., And Adj. EPS Of $6.65-$6.70 (Prior $6.60-$6.70) Vs. $6.66 Est.

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.56 by 8.97 percent. This is a 15.65 percent increase over earnings of $1.47 per share from the same period last year. The company reported quarterly sales of $378.734 million which beat the analyst consensus estimate of $371.681 million by 1.90 percent. This is a 18.37 percent increase over sales of $319.946 million the same period last year.

Earnings Beats

Lantheus Holdings Q3 2024 Adj. EPS $1.70 Beats $1.56 Estimate, Sales $378.734M Beat $371.681M Estimate

Lantheus Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NYSE">LNTH</a>) short percent of float has risen 3.19% since its last report. The company recently reported that it has 4.25 million shares sold short, which is 8.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lantheus Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730748618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lantheus Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lantheus Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lantheus Holdings's peer group average for short interest as a percentage of float is 7.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Lantheus Holdings's Recent Short Interest

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>).
On Oct. 29, Citigroup analyst Jon Tower maintained Cava Group with a Neutral and raised the price target <a href="https://www.benzinga.com/quote/CAVA/analyst-ratings">from $115 to $140.</a>
When asked about GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), he said, &#8220;You have to have planes last longer. And that means more GE business.&#8221;
On Oct. 22, GE Aerospace reported third-quarter 2024 adjusted revenue growth of 6% year-over-year to $8.943 billion and GAAP revenue of $9.84 billion. The analyst consensus was $9.022 billion.
Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is a &#8220;really good&#8221; company,&#8221; Cramer said. &#8220;It's just one of those companies that you just want to own it — I hate to say this — and forget about it, because that's how good it is.&#8221;
On Oct. 22, Stryker reported quarterly earnings of $2.87 per share which beat the analyst consensus estimate of $2.77 per share. The company reported quarterly sales of $5.49 billion which beat the analyst consensus estimate of $5.37 billion.
Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) is &#8220;very good,&#8221; he said. &#8220;It's a great place to be, particularly with all the things that are being done with AI.&#8221;
Lantheus Holdings will host a conference call on Wednesday, Nov. 6, to discuss its financial and operating results for the third quarter.
Essential Utilities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) is a &#8220;great&#8221; company, the Mad Money host said. &#8220;That is a terrific stock.&#8221;
Essential Utilities will report earnings for the quarter ending Sept. 30, after the closing bell on Nov. 4.
Price Action:
<ul>
<li>GE Aerospace shares fell 1.6% to settle at $171.78 on Thursday.</li>
<li>Stryker shares dipped 2% to close at $356.28 on Thursday.</li>
<li>Lantheus shares gained 0.4% to settle at $109.84 during the session.</li>
<li>Essential Utilities fell 0.4% to settle at $38.60 on Thursday.</li>
<li>Cava shares fell 0.2% to close at $133.56.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

CAVA

WTRG

Jim Cramer Likes Cava Group, Calls This Utilities Stock 'Terrific'

<ul>
<li>Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival</li>
<li>Overall Response Rate was&nbsp;38.1%&nbsp;vs.&nbsp;12.0%&nbsp;for the ARPI switch arm, including&nbsp;9.3%&nbsp;Complete Responses</li>
<li>Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy&mdash;Prostate (FACT-P)</li>
<li>Interim Overall Survival Crossover Adjusted Hazard Ratio was &lt;1.00 when Assessed Using Two-Stage and Inverse Probability Censoring Weighting Methods</li>
<li>Overall Survival data continue to mature, an update is expected once data are available for&nbsp;75%&nbsp;of protocol-specified target OS events</li>
</ul>

Reported Sunday, Lantheus Unveils Phase 3 SPLASH Trial Results In PSMA-Positive Metastatic Prostate Cancer At ESMO 2024

In a regulatory filing, Lantheus (LNTH) dislcosed that Jeff Humphrey, MD, is no longer Chief Medical Officer at Lantheus Holdings. His last day of ...

Lantheus announces Chief Medical Officer Jeff Humphrey MD to depart

An update from Lantheus ( ($LNTH) ) is now available. Jeff Humphrey, MD, will no longer serve as Chief Medical Officer at Lantheus Holdings, Inc., ...

Lantheus Announces Departure of Chief Medical Officer

Lazard US Equity Concentrated Portfolio Q3 2024 Commentary

Truist Financial analyst Richard Newitter maintained a Buy rating on Lantheus (LNTH – Research Report) today. The company's shares closed last Frid...

Lantheus (LNTH) Gets a Buy from Truist Financial

Lazard US Small Cap Equity Select Portfolio Q3 2024 Commentary

B.Riley Financial analyst Yuan Zhi maintained a Buy rating on Lantheus (LNTH – Research Report) on December 20 and set a price target of $146.00. T...

B.Riley Financial Sticks to Its Buy Rating for Lantheus (LNTH)

Carillon Chartwell Small Cap Growth Fund Q3 2024 Commentary

Carillon Eagle Small Cap Growth Fund Q3 2024 Commentary

Radiopharm Theranostics (RADX) has entered into a strategic co-development partnership with Lantheus (LNTH) to advance the clinical development of ...

Radiopharm enters co-development partnership with Lantheus

Lantheus Holdings: Powerhouse Potential In 2025

ADMA

ASTS

AVDX

AVTR

CELH

CHRD

COHR

FTAI

GOOG

GOOGL

LULU

ONTO

ORCL

PCVX

RADX

RMBS

SCHW

VNOM

ZETA

Press Releases

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Management

Lantheus Appoints Julie Eastland as New Board Member

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Small Cap

Opinion

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Health Care

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

Lantheus Reports Third Quarter 2024 Financial Results

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

Comments

Lantheus Holdings

Noticias

Últimas noticias sobre Lantheus Holdings (NASDAQ:LNTH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL